# Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma

> **NCT02748564** · PHASE2 · TERMINATED · sponsor: **Rutgers, The State University of New Jersey** · enrollment: 10 (actual)

## Conditions studied

- Metastatic Melanoma
- Stage III Mucosal Melanoma of the Head and Neck
- Stage IIIA Skin Melanoma
- Stage IIIB Skin Melanoma
- Stage IIIC Skin Melanoma
- Stage IV Skin Melanoma
- Stage IVA Mucosal Melanoma of the Head and Neck
- Stage IVB Mucosal Melanoma of the Head and Neck
- Stage IVC Mucosal Melanoma of the Head and Neck

## Interventions

- **BIOLOGICAL:** Aldesleukin
- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT02748564
- **Lead sponsor:** Rutgers, The State University of New Jersey
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-03-21
- **Primary completion:** 2018-10-18
- **Final completion:** 2023-06-05
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Study Complete
- **Last updated:** 2023-08-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02748564

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02748564, "Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02748564. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*